NCT03419221: TEPSTAR

Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection

Completed NA Last updated 18 April 2025

What this trial tests

NA trial testing PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions in Staphylococcus Aureus in 291 participants. Completed in 20 March 2025.

Timeline

29 January 2018

Primary endpoint
20 March 2025

20 March 2025

Quick facts

Lead sponsor	University Hospital, Montpellier
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	291
Start date	29 January 2018
Primary completion	20 March 2025
Estimated completion	20 March 2025
Sites	1 location across France

Drugs / interventions tested

• PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions
• Patients' routine care with performance of explorations based on anamnesis and clinical symptoms

Conditions studied

• Staphylococcus Aureus — all drugs for Staphylococcus Aureus →

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Staphylococcus Aureus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

S. aureus bloodstream infection (SAB) is a severe disease associated with a 30% case-fatality rate at 12 weeks. Severity of this disease is related to the high prevalence of staphylococcal Deep Foci of Infection (SA-DFI), which require prolonged duration of antimicrobial therapy and specific treatment. Timely diagnosis and management of SA-DFI is associated with an improvement of prognosis during SAB. 18 FDG PET/CT (PET/CT) is a useful tool in the diagnosis of infectious foci during bacterial infections.

An ecological study performed in the Netherlands has shown that use of PET/CT in patients with Gram positive cocci bloodstream infection was associated with an increase of detection of DFI and a decrease of recurrences and mortality compared to historical controls.

The investigators hypothesize that SAB poor prognosis is in part related to the lack of diagnosis of all infectious foci and consequently to a suboptimal treatment.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.
   Burdet C, Loubet P, Le Moing V, Vindrios W, et al · · 2018 · cited 16× · PMID 30173161 · DOI 10.1136/bmjopen-2018-023151
2. Advanced Imaging for Detection of Foci of Infection in Staphylococcus aureus Bacteremia- Can a Scan Save Lives?
   Goodman AL, Packham A, Sharkey AR, Cook GJR. · · 2023 · cited 9× · PMID 36690574 · DOI 10.1053/j.semnuclmed.2023.01.002
3. Imaging in the investigation and management of Staphylococcus aureus bacteraemia: a role for advanced imaging techniques.
   Goodman AL, Cook GJ, Goh V. · · 2020 · cited 8× · PMID 31953235 · DOI 10.1016/j.jhin.2020.01.007
4. Treatment of Complicated Gram-Positive Bacteremia and Infective Endocarditis.
   Schellong P, Joean O, Pletz MW, Hagel S, et al · · 2025 · cited 5× · PMID 39720961 · DOI 10.1007/s40265-024-02135-z
5. The role of [18F]FDG-PET/CT in Staphylococcus aureus bacteremia: A clinical perspective.
   Kouijzer IJE, Ghanem-Zoubi N. · · 2024 · cited 1× · PMID 40604126 · DOI 10.1038/s44303-024-00036-0